Back to Search
Start Over
Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres
- Source :
- J Gastrointest Oncol
- Publication Year :
- 2020
- Publisher :
- AME Publishing Company, 2020.
-
Abstract
- Background Studies have shown that the albumin-bilirubin (ALBI) grade can be a superior prognosticator for patients undergoing Yttrium-90 (Y90) glass microsphere radioembolization for hepatocellular carcinoma (HCC) compared to the Child-Pugh (CP) scoring system. Less is known about the applicability of this score in non-hepatocellular malignancies using Y90 resin microspheres. This study evaluates the ALBI grade's ability to predict overall survival and biochemical toxicity in patients undergoing resin Y90 radioembolization and body surface area dosimetry (BSA) for non-hepatocellular primary and metastatic liver malignancies compared to the CP class and Model for End-Stage Liver Disease (MELD) score. Methods A retrospective review of patients with intrahepatic metastatic colorectal and neuroendocrine cancers and cholangiocarcinoma undergoing resin radioembolization from 2006-2015 at a single tertiary medical center was performed. ALBI, MELD, and CP scores were compared and correlated with biochemical toxicity and overall survival. Results There was a significant difference in overall survival between CP class A and class B liver function (P=0.04) for the entire patient cohort. ALBI grade (P=0.36) and MELD score (P=0.19) were not independently associated with survival. When stratified by CP class, the ALBI grade revealed a trend for survival difference in CP class B (P=0.05). Baseline ALBI grade was associated with post-procedural albumin reduction (P=0.01) and bilirubin elevation (P=0.007). Conclusions ALBI grade predicted post-procedural biochemical toxicity, but did not predict survival after resin radioembolization of non-hepatocellular liver malignancies using BSA dosimetry. Given the heterogeneity of this study population, dedicated prospective analyses are required.
- Subjects :
- Body surface area
medicine.medical_specialty
Bilirubin
business.industry
Gastroenterology
Albumin
medicine.disease
Malignancy
03 medical and health sciences
Liver disease
chemistry.chemical_compound
0302 clinical medicine
Oncology
chemistry
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Internal medicine
Toxicity
medicine
Original Article
030211 gastroenterology & hepatology
Liver function
business
Subjects
Details
- ISSN :
- 2219679X and 20786891
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Journal of Gastrointestinal Oncology
- Accession number :
- edsair.doi.dedup.....6963b9f9f197d704fcb7d97139d581ea